Improving Outcomes in EGFR-Mutated Non-Small-Cell Lung Cancer: Global Insights on Evolving Practice Standards

In this episode, Enriqueta Felip, MD, PhD, and Matthew Gubens, MD, MS, discuss evolving practice standards for EGFR-mutated non-small-cell lung cancer with topics including:Biomarker testing and strategiesOptimal first-line therapy in patients with NSCLCManagement of patients with CNS diseaseSelecting therapy for patients with noncanonical mutationsManagement strategies after progression on first-line EGFR TKI therapySelecting therapy for patients with early stage diseasePresenters: Enriqueta Felip, MD, PhDHead, Thoracic Oncology UnitOncology ServiceVall d'Hebron University HospitalBarcelona, SpainMatthew Gubens, MD, MSAssociate ProfessorThoracic OncologyUniversity of California, San FranciscoSan Francisco, CaliforniaContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program, including associated downloadable slidesets:https://bit.ly/2PpFFHM

There are no comments yet.

Please log in to write the first comment.